Corrections & amendments

6

Author Correction: CAR-T cell therapy-related cytokine release syndrome and therapeutic response is modulated by the gut microbiome in hematologic malignancies

Correction to: *Nature Communications* https://doi.org/10.1038/s41467-022-32960-3, published online 09 September 2022

https://doi.org/10.1038/s41467-024-47038-5

Published online: 27 March 2024

Check for updates

Yongxian Hu, Jingjing Li[®], Fang Ni, Zhongli Yang, Xiaohua Gui, Zhiwei Bao, Houli Zhao, Guoqing Wei, Yiyun Wang, Mingming Zhang, Ruimin Hong, Linqin Wang, Wenjun Wu, Mohamad Mohty, Arnon Nagler, Alex H. Chang[®], Marcel R. M. van den Brink[®], Ming D. Li & He Huang[®]

The original version of this Article had numerical mistakes in the source data corresponding to figure 1a, some values (or textual entries) were missing (cells 1P, 18P), and some were incorrect (cells 3Q, 4J, 11J-P, 17K-L, 18N, 30B, 30E, 30J-K, 30N, 39E, 39J, 40E, 40J, 41E, 54J, 63J-L, 65B, 65K, 65N, 73E, 73J, 74E, 74J, 78N-P, 85J). These are replaced with the correct entries.

Column B of the source data corresponding to Supplementary Table 1 is now deleted, due to confidentiality concerns.

Accordingly, the text of the "Clinical trial outcomes" section of the Results has been corrected:

Line 10: "Within 1 month after BCMA CAR-T cell infusion, 2 patients died of cerebral hemorrhage and 4 died of severe infections.

Of the 95 evaluable patients, 91 (95.8%) had an overall response."

Line 13: "With a median follow-up time of 21.2 months (95% CI, 18.4–32.1), the median progression-free survival (PFS) was 12.0 (95% CI, 8.1–15.7) months. The 1-year OS and PFS rates were 0.70 (95% CI, 0.61–0.80) and 0.48 (95% CI, 0.39–0.59), respectively.

Additional information

Supplementary information The online version contains supplementary material available at https://doi.org/10.1038/s41467-024-47038-5.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

© The Author(s) 2024